Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human relaxin-1 is a synthetic peptide developed by Relaxera that mimics the endogenous human H1 relaxin hormone. It functions as a dual agonist of the relaxin-family peptide receptors RXFP1 and RXFP2. While human relaxin-2 (H2) is the most studied member of the family and the primary circulating form in humans, relaxin-1 is known to be expressed in specific tissues such as the decidua, trophoblast, and prostate, suggesting localized physiological roles. Relaxera's synthetic version is utilized in preclinical research to explore therapeutic potential in areas such as fibrosis, cardiovascular disease, and reproductive health, leveraging the peptide's ability to modulate extracellular matrix metabolism, promote vasodilation, and exert anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human relaxin-1.